Clinical trial · Interventional
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)
NCT00231166CI-TRIAL-00035228completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HCD122 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HCD122
- interventionNames
- Drug: HCD122
Primary outcomes (1)
- measure
- Safety, pharmacokinetics and pharmacodynamics at multiple doses
- timeFrame
- At the completion of each dose escalation cohort
Secondary outcomes (1)
- measure
- Clinical response after various doses
- timeFrame
- Once a month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical Diagnosis of MM requiring treatment * Refractory or Relapsed Disease * At least one prior treatment regimen * Male or Female * \>18 years of age Exclusion Criteria: * Prior Allogeneic bone marrow transplant (prior autologous transplant allowed) * Intracranial disease or epidural disease * Clinically significant cardiac dysfunction or other significant organ dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.